Search results for "Row"

showing 10 items of 9311 documents

Corneal opacity and copper levels of the Lewis syndrome after systemic chemotherapy

2020

Abstract Purpose To report a female patient of biclonal Lewis syndrome which consists of a trias: biclonal gammopathy of undetermined significance, paraproteinemic keratopathy in form of a brownish discoid opacification at the level of Descemet's membrane and hypercupremia. After several years there was a conversion to multiple myeloma. Systemic chemotherapy led to a complete remission of multiple myeloma and to a normalization of the copper level in the blood that lasted five years. The corneal opacification remained unchanged. Observations A currently 66-year-old woman suffered from biclonal Lewis syndrome. On both eyes there is a central discoid yellow-brownish discoloration in the Pre-D…

medicine.medical_specialtymedicine.medical_treatmentUnchanged corneal opacity after chemotherapyGastroenterology03 medical and health sciences0302 clinical medicinelcsh:OphthalmologyChemotherapy-induced normal level of copper in serumInternal medicineMedicineAffinity of IgG to copper in Lewis syndromeCopper levelsProgressive anemiaMultiple myelomaLewis syndromeHypercupremiaChemotherapyBiclonal gammopathybusiness.industrySystemic chemotherapyHypercupremiaCorneal opacitymedicine.diseaseOphthalmologylcsh:RE1-994030221 ophthalmology & optometrybusinessDiscoid brownish opacification of Descemet membrane030217 neurology & neurosurgeryAmerican Journal of Ophthalmology Case Reports
researchProduct

Bone marrow evaluation according to the PVSG and WHO criteria in 90 essential thrombocythemia (ET) patients treated with PEG interferon alpha-2b. Pre…

2005

Abstract Ninety ET patients diagnosed according to the PVSG criteria were enrolled in a phase II study (sponsored by the Schering-Plough Company) designed to evaluate the efficacy, safety and tolerability of a two years treatment with PEG Interferon alpha-2 b (PEG Intron). The patients, observed in 16 Italian Centres belonging to the GIMEMA Cooperative Group and judged at high risk, had been previously treated with cytoreductive (97%) and antiplatelet (91%) drugs. At the study start the patients, 60 F and 30 M, mean age 45 years, showed splenomegaly in 22% of cases. The Hematological Response (HR: PLT<500 x109/L) was observed in 64/81 (79%) and 48/55 (87%) of the patients on PEG Intr…

medicine.medical_specialtythrombocythemia (ET) patientsImmunologyEssential Thrombocythemia (ET); PEG Interferon alpha-2b.Phases of clinical researchAlpha (ethology)BiochemistryGastroenterologyPEG Interferon alpha-2bFibrosisInternal medicinePEG ratioBiopsyMedicineEssential Thrombocythemia (ET)medicine.diagnostic_testbusiness.industryEssential thrombocythemiaCell BiologyHematologymedicine.diseaseSurgerymedicine.anatomical_structureTolerabilityBone marrow evaluationBone marrowbusiness
researchProduct

Positive and negative effects of trauma in patients after myocardial infarction : The role of type D personality

2020

Background: Experiencing a myocardial infarction threatens the health and life of the patient; therefore, it can be perceived as a traumatic event. Indeed, myocardial infarction may result in negative consequences, including symptoms of posttraumatic stress disorder (PTSD). However, it is also possible to experience positive effects from traumatic events, which is expressed as posttraumatic growth. Personality characteristics, including type D (i.e., distressed) personality, are among several factors that have been shown determine the occurrence of negative and positive consequences after exposure to trauma. Aim of the study: The aim of the present study was to establish the role of distres…

medicine.medical_specialtytype D personalitybusiness.industryType D personalityposttraumatic growthmedicine.diseaseposttraumatic stresstraumamyocardial infarctionInternal medicinemental disordersCardiologyMedicineIn patientMyocardial infarctionbusinessMedical Science Pulse
researchProduct

INHIBITION OF CELLULAR GROWTH AND STEROID 11β-HYDROXYLATION INRAS-TRANSFORMED ADRENOCORTICAL CELLS BY THE FUNGAL TOXINS BETICOLINS

1996

Abstract The proliferation of GM16 and 4CDTras-transformed newborn rat adrenocortical (RTAC) cells and Y1 mouse adrenal tumor cells was inhibited by beticolins, the fungal toxins extracted fromCercospora beticola, at submicromolar concentrations in a dose-dependent manner. Inhibitory concentrations for half the maximum inhibition were 150, 75 and 25 n M for beticolin-1 and 230, 150 and 50 n M for beticolin-2 in GM16, 4CDT and Y1 cells respectively. Beticolins strongly inhibited the production of 11β-hydroxysteroids on the second and third days of treatment in a dose-dependent manner between 0.1 and 1 μ M . Beticolins were shown by confocal microscopy to be localized in cytoplasmic organelle…

medicine.medical_treatmentAdrenal Gland NeoplasmsBiologyTransfectionHeterocyclic Compounds 4 or More RingsSteroidlaw.inventionHydroxylationMiceStructure-Activity Relationshipchemistry.chemical_compoundConfocal microscopylawOrganelleTumor Cells CulturedmedicineAnimalsCells CulturedHydroxysteroidsMicroscopy ConfocalDose-Response Relationship DrugCell growthCell BiologyGeneral MedicineMycotoxinsGrowth InhibitorsNeoplasm ProteinsRatsCell Transformation NeoplasticGenes rasAnimals NewbornchemistryBiochemistryCytoplasmAdrenal CortexSteroid 11-beta-HydroxylaseSignal transductionGrowth inhibitionCell DivisionCell Biology International
researchProduct

Novel Combination of Sorafenib and Celecoxib Provides Synergistic Anti-Proliferative and Pro-Apoptotic Effects in Human Liver Cancer Cells

2013

Molecular targeted therapy has shown promise as a treatment for advanced hepatocellular carcinoma (HCC). Sorafenib, a multikinase inhibitor, recently received FDA approval for the treatment of advanced HCC. However, although sorafenib is well tolerated, concern for its safety has been expressed. Celecoxib (Celebrex®) is a selective cyclooxygenase-2 (COX-2) inhibitor which exhibits antitumor effects in human HCC cells. The present study examined the interaction between celecoxib and sorafenib in two human liver tumor cell lines HepG2 and Huh7. Our data showed that each inhibitor alone reduced cell growth and the combination of celecoxib with sorafenib synergistically inhibited cell growth an…

medicine.medical_treatmentCancer TreatmentGene ExpressionApoptosisPharmacologyBiochemistryTargeted therapy0302 clinical medicineMolecular Cell Biology0303 health sciencesSulfonamidesMultidisciplinaryReverse Transcriptase Polymerase Chain ReactionQLiver NeoplasmsRDrug SynergismGenomicsSorafenib3. Good healthGene Expression Regulation NeoplasticOncology030220 oncology & carcinogenesisMedicineLiver cancermedicine.drugResearch ArticleBiotechnologySignal TransductionSorafenibNiacinamideProgrammed cell deathCarcinoma HepatocellularScienceBlotting WesternBiologyMolecular Genetics03 medical and health sciencesCell Line TumorGastrointestinal TumorsmedicineIn Situ Nick-End LabelingHumansneoplasmsBiology030304 developmental biologyCell ProliferationDNA PrimersHuman liver cancer Apoptosis Sorafenib Celecoxib anti-proliferative effectsCell growthGene Expression ProfilingPhenylurea CompoundsComputational BiologyCancers and NeoplasmsHepatocellular CarcinomaChemotherapy and Drug Treatmentmedicine.diseaseMicroarray Analysisdigestive system diseasesGene expression profilingApoptosisCell cultureCelecoxibPyrazolesGenome Expression AnalysisPLoS ONE
researchProduct

Immunologic microenvironment and personalized treatment in multiple myeloma.

2013

Introduction: Multiple myeloma (MM) is characterized by generalized immune suppression and increased susceptibility to infections and secondary malignancies. Malignant plasma cells (PCs) modulate the bone marrow microenvironment to favor their own survival and proliferation. These events lead to a severe deregulation of immune effectors. Extensive studies have been conducted to unveil the mechanisms through which MM cells negatively modulate immunity and to develop therapeutical approaches for restoring an efficient anti-MM immune response. Areas covered: This review article covers both the immunosuppressive effects exerted by MM and the immunomodulatory potential of novel anti-MM agents. A…

medicine.medical_treatmentClinical BiochemistryAntineoplastic AgentsImmune systemImmunityDrug DiscoveryTumor MicroenvironmentMedicineHumansPrecision MedicineMultiple myelomaBone marrow microenvironmentPharmacologyTumor microenvironmentbusiness.industryImmunotherapymedicine.diseaseReview articlemedicine.anatomical_structurePersonalized treatmentImmune SystemImmunologyBone marrowPersonalized medicineImmunotherapybusinessMultiple MyelomaExpert opinion on biological therapy
researchProduct

Optimized culture conditions for tissue explants of uterine leiomyoma

2012

Background Uterine leiomyomas are the most common benign tumours in women, which arise from smooth muscle cells of the uterine myometrium and usually are multicentric. In spite of their frequency pathogenesis is widely unknown, mainly due to the absence of a suitable model system. We describe the systematic optimization of culturing leiomyoma tissue explants in an economical and effective ex vivo system. Methods Different concentrations of oxygen, different media, sera, hormones, and growth factor supplements were tested. Immunohistochemical stainings with antibodies against hormone receptors as well as specifying proliferation and apoptotic indices and real-time PCR were performed. Results…

medicine.medical_treatmentCulture Media; Epidermal Growth Factor; Estradiol; Female; Humans; Immunohistochemistry; Leiomyoma; Progesterone; RNA Messenger; Real-Time Polymerase Chain Reaction; Uterine NeoplasmsBiologyReal-Time Polymerase Chain ReactionGeneral Biochemistry Genetics and Molecular BiologyAndrologyTissue culturemedicineHumansRNA MessengerUterine NeoplasmProgesteroneUterine leiomyomaEpidermal Growth FactorEstradiolLeiomyomaGrowth factorMyometriummedicine.diseaseImmunohistochemistrySettore MED/40 - Ginecologia E OstetriciaCulture MediaLeiomyomaHormone receptorUterine NeoplasmsFemaleEx vivoHuman
researchProduct

Host-Derived CD8+ Dendritic Cells Protect Against Acute Graft-versus-Host Disease after Experimental Allogeneic Bone Marrow Transplantation

2014

Graft-versus-host disease (GVHD) is a frequent life-threatening complication after allogeneic hematopoietic stem cell transplantation (HSCT) and induced by donor-derived T cells that become activated by host antigen-presenting cells. To address the relevance of host dendritic cell (DC) populations in this disease, we used mouse strains deficient in CD11c(+) or CD8α(+) DC populations in a model of acute GVHD where bone marrow and T cells from BALB/c donors were transplanted into C57BL/6 hosts. Surprisingly, a strong increase in GVHD-related mortality was observed in the absence of CD11c(+) cells. Likewise, Batf3-deficient (Batf3(-/-)) mice that lack CD8α(+) DCs also displayed a strongly incr…

medicine.medical_treatmentGraft vs Host DiseasePriming (immunology)CD11cHematopoietic stem cell transplantationchemical and pharmacologic phenomenaHematopoietic stem cell transplantationCD8-Positive T-LymphocytesBiologyGraft-versus-host diseaseDendritic cellsMiceimmune system diseasesBATF3medicineAnimalsTransplantation HomologousBone Marrow TransplantationMice Inbred BALB CTransplantationPeripheral toleranceHematologyDendritic cellmedicine.diseaseMice Inbred C57BLsurgical procedures operativeGraft-versus-host diseasemedicine.anatomical_structureImmunologyBone marrowCD8Biology of Blood and Marrow Transplantation
researchProduct

Murine bone marrow-derived mast cells as potent producers of IL-9: costimulatory function of IL-10 and kit ligand in the presence of IL-1.

2000

Abstract Recently, the Th2-type cytokine IL-9 was identified by genetic mapping analyses as a key mediator that determines the susceptibility to asthma. This has been further supported by data from IL-9-transgenic mice in which the overexpression of IL-9 in the lung causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness. In an accompanying paper, we demonstrate that murine bone marrow-derived mast cells (BMMC) after stimulation with either ionomycin, a combination of ionomycin and IL-1, or via IgE-Ag complexes and IL-1 are very potent producers of IL-9. Herein we show that a dramatic increase of IL-9 production is observed when BMMC activated with ionomycin/IL-…

medicine.medical_treatmentImmunologyEndogenyStem cell factorBone Marrow CellsBiologychemistry.chemical_compoundMiceAdjuvants ImmunologicmedicineImmunology and AllergyAnimalsMast CellsRNA MessengerReporter geneMice Inbred BALB CStem Cell FactorInterleukin-9TransfectionMolecular biologyInterleukin-10Interleukin 10medicine.anatomical_structureCytokinechemistryGene Expression RegulationIonomycinImmunologyBone marrow5' Untranslated RegionsInterleukin-1Journal of immunology (Baltimore, Md. : 1950)
researchProduct

Granulocyte-macrophage colony-stimulating factor (CSF) and multilineage CSF recruit human monocytes to express granulocyte CSF

1989

Abstract We assessed the capacity of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) and multilineage (Multi)-CSF to induce release of granulocyte-CSF (G-CSF) by highly purified peripheral blood monocyte (Mo) preparations. Our results reveal that GM-CSF and Multi-CSF, either alone or in a synergistic concert, activate Mo to transcribe G-CSF messenger (m) RNA and release biologically active G- CSF protein into their culture supernatants. G-CSF had no regulatory effect on Mo expression of cytoplasmic G-CSF mRNA levels and G-CSF protein secretion by itself. These differential actions of CSFs provide further insight into self-regulatory mechanisms within the growth f…

medicine.medical_treatmentImmunologyGranulocyteBiologyBiochemistryMonocyteslaw.inventionColony-Stimulating FactorslawmedicineHumansRNA MessengerGrowth SubstancesCells CulturedCSF albuminCell-Free SystemGrowth factorGranulocyte-Macrophage Colony-Stimulating FactorRNABiological activityCell BiologyHematologyMolecular biologyRecombinant ProteinsDrug CombinationsGranulocyte macrophage colony-stimulating factorSecretory proteinmedicine.anatomical_structureImmunologyRecombinant DNAGranulocytesmedicine.drugBlood
researchProduct